Press Releases
Ionis to hold virtual investor day event
Welcome and introductions |
|
Where we are today |
|
Key commercial opportunities in Ionis' cardiovascular franchise |
|
Key commercial opportunities in Ionis' neurological franchise |
|
Commercial strategy |
|
Valuing Ionis' pipeline |
|
Increasing our leadership position in RNA-targeted therapeutics |
|
2021 and beyond |
|
Q&A |
All |
Interested parties may access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.
About
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.
To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-to-hold-virtual-investor-day-event-301182098.html
SOURCE
Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Investor Relations, 760-603-2741 OR Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Corporate Communications, 760-603-4679